Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07948447
PHASE1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants

Sponsor: NeolaiaBio

View on ClinicalTrials.gov

Summary

NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.

Official title: A Phase 1, First-In-Human, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-12

Completion Date

2027-05

Last Updated

2026-11-19

Healthy Volunteers

Yes

Interventions

DRUG

NEO-1306

NEO-1306, single Dose #1

DRUG

NEO-1306

NEO-1306, single Dose #2

DRUG

NEO-1306

NEO-1306, single Dose #3

DRUG

NEO-1306

NEO-1306, single Dose #4

DRUG

NEO-1306

NEO-1306, single Dose #5

DRUG

NEO-1306

NEO-1306, single Dose #6

DRUG

NEO-1306

NEO-1306, Multiple Dose #1, single dose once per day for 14 days

DRUG

NEO-1306

NEO-1306, Multiple Dose #2, single dose once per day for 14 days

DRUG

NEO-1306

NEO-1306, Multiple Dose #3, single dose once per day for 14 days

DRUG

NEO-1306

NEO-1306, Multiple Dose #4, single dose once per day for 14 days

DRUG

NEO-1306 Placebo

SAD Placebo

DRUG

NEO-1306 Placebo

MAD Placebo

Locations (1)

CMAX Clinical Research

Adelaide, South Australia, Australia